BioArctic Outlicenses Alpha-Synuclein Portfolio To AbbVie For Parkinson's

 
• By Sten Stovall
  
Parkinson's disease. 3D illustration showing neurons containing Lewy bodies small red spheres which are deposits of proteins accumulated in brain cells that cause their progressive degeneration - Illustration
BAN0805 is most advanced alpha-synuclein targeting antibody in BioArctic's portfolio • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business